These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 23161875)
1. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Lee SL; Tan BS; Chan LC J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875 [TBL] [Abstract][Full Text] [Related]
2. [Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab]. Coquart N; Karam A; Metges JP; Misery L Ann Dermatol Venereol; 2010 Apr; 137(4):306-7. PubMed ID: 20417368 [No Abstract] [Full Text] [Related]
3. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. Ocvirk J; Cencelj S J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151 [TBL] [Abstract][Full Text] [Related]
7. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. Fox LP J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969 [TBL] [Abstract][Full Text] [Related]
8. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Cohen PR; Escudier SM; Kurzrock R Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623 [TBL] [Abstract][Full Text] [Related]
9. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Shu KY; Kindler HL; Medenica M; Lacouture M Br J Dermatol; 2006 Jan; 154(1):191-2. PubMed ID: 16403122 [No Abstract] [Full Text] [Related]
10. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360 [TBL] [Abstract][Full Text] [Related]
11. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dainichi T; Tanaka M; Tsuruta N; Furue M; Noda K Dermatology; 2003; 207(3):324-5. PubMed ID: 14571080 [No Abstract] [Full Text] [Related]
12. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor. Gencoglan G; Ceylan C Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540 [TBL] [Abstract][Full Text] [Related]
17. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab. Bragg J; Pomeranz MK Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934 [TBL] [Abstract][Full Text] [Related]
18. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. Kiyohara Y; Yamazaki N; Kishi A J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600 [TBL] [Abstract][Full Text] [Related]
19. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348 [TBL] [Abstract][Full Text] [Related]
20. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]